RA
RIGL icon

Royce & Associates’s Rigel Pharmaceuticals RIGL Stock Holding History

Royce & Associates’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,412
Closed -$37K – 1011
2021
Q4 		$37K Buy
+1,412
New +$42.6K ﹤0.01% 966
2015
Q1 		– Sell
-21,539
Closed -$489K – 1288
2014
Q4 		$489K Hold
21,539
– – ﹤0.01% 1134
2014
Q3 		$418K Hold
21,539
– – ﹤0.01% 1226
2014
Q2 		$782K Sell
21,539
-9,400
-30% -$320K ﹤0.01% 1175
2014
Q1 		$1.2M Buy
30,939
+40
+0.1% +$1.43K ﹤0.01% 1124
2013
Q4 		$881K Buy
30,899
+6,299
+26% +$185K ﹤0.01% 1184
2013
Q3 		$881K Hold
24,600
– – ﹤0.01% 1191
2013
Q2 		$822K Buy
+24,600
New +$1.11M ﹤0.01% 1183

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Royce & Associates's RIGL Position: Q1 2022 in Review

Royce & Associates sold out of Rigel Pharmaceuticals (RIGL) in Q1 2022, closing a stake of 1,412 shares — an estimated $37K sold.

Royce & Associates first reported a position in RIGL in Q2 2013 and held it in 8 quarters. The position peaked at $1.2M in Q1 2014. 164 funds tracked by Wall St. Rank hold RIGL as of Q1 2022.

  • Royce & Associates reported no remaining Rigel Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Royce & Associates sold 1,412 Rigel Pharmaceuticals shares in Q1 2022, an estimated $37K.
  • Royce & Associates first reported a position in Rigel Pharmaceuticals in Q2 2013 and held it in 8 quarters.
  • Royce & Associates's Rigel Pharmaceuticals position peaked at $1.2M in Q1 2014.
  • 164 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2022.

Based on Royce & Associates's 13F filing for Q1 2022, filed 5 May 2022.